期刊文献+

辅酶Q10对乳腺癌患者化疗期间主要不良心血管事件的影响

Effect of coenzyme Q Effect of coenzyme Q10 on major adverse cardiovascular event during chemotherapy in breast cancer patients
下载PDF
导出
摘要 目的探讨辅酶Q10(CoQ10)对乳腺癌患者化疗期间主要不良心血管事件(MACE)的影响。方法根据化疗期间是否使用CoQ10将122例乳腺癌患者分为对照组(n=68,未使用CoQ10)和观察组(n=54,使用CoQ10),比较两组患者MACE发生情况。根据MACE发生情况将所有患者分为MACE组和非MACE组,比较两组患者的临床特征,采用Logistic回归模型分析乳腺癌患者化疗期间发生MACE的影响因素。结果观察组患者MACE发生率为22.22%,低于对照组患者的44.12%,差异有统计学意义(P<0.05)。122例患者中,发生MACE 42例,MACE发生率为34.43%。MACE组患者中年龄≥50岁、合并高血压、合并高血脂、化疗期间未使用CoQ10的比例均高于非MACE组,差异均有统计学意义(P<0.05)。多因素Logistic回归分析结果显示,合并高血压、合并高血脂、化疗期间未使用CoQ10均是乳腺癌患者化疗期间发生MACE的危险因素(P<0.01)。结论乳腺癌患者化疗期间MACE发生率较高,CoQ10能够降低MACE发生率,MACE的发生与高血压、高血脂密切相关,应给予密切关注。 Objective To explore the effect of coenzyme Q10(CoQ10)on major adverse cardiovascular event(MACE)during chemotherapy in breast cancer patients.Method According to whether or not CoQ10 was used during chemotherapy,122 breast cancer patients were divided into control group(n=68,CoQ10 was not used)and observation group(n=54,CoQ10 was used),and the occurrence of MACE between the two groups was compared.According to the occurrence of MACE,all patients were divided into MACE group and non-MACE group,the clinical features of the two groups were compared,and the influencing factors of MACE in breast cancer patients during chemotherapy were analyzed by Logistic regression model.Result The incidence of MACE in observation group was 22.22%,lower than 44.12%in control group,and the difference was statistically significant(P<0.05).Among 122 patients,MACE occurred in 42 patients,and the incidence rate of MACE was 34.43%.The proportions of patients with age≥50 years old,hypertension,hyperlipidemia and non-use of CoQ10 during chemotherapy in MACE group were higher than those in non-MACE group,and the differences were statistically significant(P<0.05).Multivariate Logistic regression analysis showed that hypertension,hyperlipidemia and non-use of CoQ10 during chemotherapy were risk factors for MACE in breast cancer patients during chemotherapy(P<0.01).Conclusion The incidence of MACE is high in breast cancer patients during chemotherapy,and CoQ10 can reduce the incidence of MACE.The occurrence of MACE is closely related to hypertension and hyperlipidemia,which should be paid close attention to.
作者 林伟玲 张根玲 袁景丽 LIN Weiling;ZHANG Genling;YUAN Jingli(Department of Breast,Zhengzhou Traditional Chinese Medicine Hospital,Zhengzhou 450000,He’nan,China;Department of Ultrasound,Public People’s Hospital of Xinzheng,Zhengzhou 450000,He’nan,China;Department of Anesthesiology,the First Affiliated Hospital of He’nan University of Chinese Medicine,Zhengzhou 451100,He’nan,China)
出处 《癌症进展》 2024年第19期2163-2166,共4页 Oncology Progress
基金 河南省中医药科学研究专项课题(2024ZY3101)。
关键词 辅酶Q10 乳腺癌 化疗 主要不良心血管事件 危险因素 coenzyme Q10 breast cancer chemotherapy major adverse cardiovascular event risk factor
  • 相关文献

参考文献9

二级参考文献81

  • 1万新焕,王瑜亮,周长征,郭浩,马山,王立柱.丹参化学成分及其药理作用研究进展[J].中草药,2020,51(3):788-798. 被引量:411
  • 2李伟,石丰榕,任珊,黄志武,韦桂喜.血清cTnI联合BNP检测在乳腺癌化疗相关心脏毒性早期预测中的应用评价[J].实用妇科内分泌电子杂志,2020,7(14):124-124. 被引量:1
  • 3张继忠,迟莉丽,沈亚领.辅酶Q_(10)的生产及在医学领域中的应用[J].上海应用技术学院学报(自然科学版),2004,4(4):301-305. 被引量:26
  • 4江泽飞,姚开泰,宋三泰.乳腺癌治疗的新循证医学证据和临床实践[J].中华医学杂志,2005,85(43):3025-3027. 被引量:29
  • 5NCCN乳腺癌临床实践指南(中国版)专家组.NCCN乳腺癌临床实践指南(中国版).2008-09-28[OL/DA].http://www.nccn-china.org/images/2008PDF/2008%20Breast%20Cancer%20guideline%20Chinese%20edition.pdf.
  • 6Ragaz J, Olivotto ZA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy : 20-year results of the British Columbia randomized trial. J Natl Cancer Inst,2005 ,97 :116-126.
  • 7Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ : ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol,2006,24 : 3381-3387.
  • 8Jones SE, Holmes FA, OShaughnessy JA,et al. Extended follow- up and analysis by age of the US Oncology Adjuvant Trial 9735 : docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well- tolerated in women 65 or older. Breast Cancer Res Treat, 2007, 106 suppl 1 : S5-11.
  • 9Gol~lhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Annals of Oncology, 2007, 18: 1133-1144.
  • 10Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor- positive breast cancer. J Clin Oncol, 2006, 24:3726-3734.

共引文献147

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部